Compare SLN & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLN | CRAI |
|---|---|---|
| Founded | 1994 | 1965 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2010 | 1998 |
| Metric | SLN | CRAI |
|---|---|---|
| Price | $19.78 | $198.28 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $19.75 | ★ $250.50 |
| AVG Volume (30 Days) | ★ 4.3M | 94.8K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 20.77 |
| EPS | N/A | ★ 8.14 |
| Revenue | $559,000.00 | ★ $751,583,000.00 |
| Revenue This Year | N/A | $9.41 |
| Revenue Next Year | $131.31 | $4.11 |
| P/E Ratio | ★ N/A | $24.23 |
| Revenue Growth | N/A | ★ 9.33 |
| 52 Week Low | $4.19 | $132.17 |
| 52 Week High | $19.87 | $227.29 |
| Indicator | SLN | CRAI |
|---|---|---|
| Relative Strength Index (RSI) | 78.28 | 62.99 |
| Support Level | $13.01 | $154.03 |
| Resistance Level | $19.87 | $204.94 |
| Average True Range (ATR) | 0.07 | 7.87 |
| MACD | -0.10 | -0.20 |
| Stochastic Oscillator | 60.42 | 46.65 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.